Recordati Industria Chimica e Farmaceutica

Transaction in Own Shares • Dec 14, 2022

NEWS RELEASE

RECORDATI: UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM

Milan, 14 th December 2022 – Within the Recordati's share buy-back program communicated to the market and initiated on 20 th June 2022 , as per authorization granted by the Shareholders' Meeting held on 29 th April 2022, with the object of the servicing of current and future stock option plans in favour of Recordati Group's management or share-based incentive plans that should be approved by the Company in the future, the Company communicates the following purchase transactions of Recordati shares pursuant to art. 2, paragraph 3, of the EU Delegated Regulation 2016/1052/UE, on the basis of the information provided by UBS Europe SE as intermediary in charge of executing, in full independency, the share buy-back program on behalf of the Company.

Aggregate details of daily transactions made on 8th and 9 th December 2022¹ in Recordati ordinary shares (ISIN IT0003828271) are as follows:

th DECEMBER TH DECEMBER SUMMARY OF PURCHASE TRANSACTIONS FROM 8 TO 9 2022
Date	Type of Transaction	Quantity	Weighted average price	Exchange
			(Euro)
08/12/2022	Purchase	4,564	40.3575	MTA
09/12/2022	Purchase	166	40.5400	MTA
TOTAL		4,730	40.3639

The details of all the purchase transactions carried out in the period indicated above are reported in the following pages.

On 9 th December 2022, the Company held no. 3,643,797 treasury shares which amount to 1.742% of the current share capital.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and the other C.I.S. countries, Ukraine, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2021 was € 1,580.1 million, operating income was € 490.2 million and net income was € 386.0 million.

For further information:

Recordati website: www.recordati.it

1 For sake of clarity it should be noted that the Company did not carry out purchase transactions from 26th November 2022 to 7th December 2022.

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office Via Matteo Civitali, 1 20148 Milano, Italy Ph. (39) 02 487871 Fax (39) 02 40073747 www.recordati.com Share Capital € 26.140.644,50 fully paid-up Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150 Tax Code/VAT No. 00748210150 Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.àr.l

Investor Relations Investor Relations Media Relations (39) 02 48787146 (39) 02 48787213 (39) 02 9288 6200

Federica De Medici Lucia Abbatantuoni Brunswick: Barbara Scalchi / Andrea Mormandi e-mail: investorelations@recordati.it e-mail: investorelations@recordati.it e-mail: recordati@brunswickgroup.com

Attachment: Daily details of transactions

Trade Date	Trade Time	Currency	Exchange	Trade Price	Quantity
	(GMT)
08/12/2022	09:50:45	EUR	MTA	40,4000	58
08/12/2022	10:06:47	EUR	MTA	40,5400	161
08/12/2022	10:35:29	EUR	MTA	40,4500	137
08/12/2022	10:53:57	EUR	MTA	40,3000	108
08/12/2022	11:00:05	EUR	MTA	40,3200	140
08/12/2022	11:12:16	EUR	MTA	40,3600	141
08/12/2022	11:44:02	EUR	MTA	40,3300	162
08/12/2022	11:58:46	EUR	MTA	40,2000	55
08/12/2022	11:58:46	EUR	MTA	40,2000	108
08/12/2022	12:01:02	EUR	MTA	40,2100	90
08/12/2022	12:01:02	EUR	MTA	40,2100	73
08/12/2022	12:10:43	EUR	MTA	40,1300	158
08/12/2022	12:20:15	EUR	MTA	40,1800	168
08/12/2022	12:29:53	EUR	MTA	40,2400	53
08/12/2022	12:29:53	EUR	MTA	40,2400	86
08/12/2022	12:39:30	EUR	MTA	40,2600	99
08/12/2022	12:39:30	EUR	MTA	40,2600	39
08/12/2022	12:44:55	EUR	MTA	40,2700	59
08/12/2022	12:49:10	EUR	MTA	40,2700	31
08/12/2022	12:49:10	EUR	MTA	40,2700	113
08/12/2022	12:51:49	EUR	MTA	40,3200	118
08/12/2022	12:51:49	EUR	MTA	40,3200	36
08/12/2022	13:00:07	EUR	MTA	40,3200	40
08/12/2022	13:05:25	EUR	MTA	40,3200	136
08/12/2022	13:09:26	EUR	MTA	40,3200	146
08/12/2022	13:16:30	EUR	MTA	40,3600	167
08/12/2022	13:20:26	EUR	MTA	40,2900	165
08/12/2022	13:26:12	EUR	MTA	40,3500	160
08/12/2022	13:27:56	EUR	MTA	40,3500	161
08/12/2022	13:30:22	EUR	MTA	40,4200	69
08/12/2022	13:30:23	EUR	MTA	40,4700	219
08/12/2022	13:30:26	EUR	MTA	40,4600	168
08/12/2022	13:30:33	EUR	MTA	40,4600	100
08/12/2022	13:30:33	EUR	MTA	40,4600	90
08/12/2022	13:31:17	EUR	MTA	40,4400	75
08/12/2022	13:31:17	EUR	MTA	40,4400	83
08/12/2022	13:37:45	EUR	MTA	40,4500	131

08/12/2022	13:37:58	EUR	MTA	40,4500	5
08/12/2022	13:46:43	EUR	MTA	40,5300	146
08/12/2022	14:00:20	EUR	MTA	40,5200	146
08/12/2022	14:06:07	EUR	MTA	40,5100	41
08/12/2022	14:06:07	EUR	MTA	40,5100	123
09/12/2022	08:22:10	EUR	MTA	40,5400	24
09/12/2022	08:22:10	EUR	MTA	40,5400	142